By Jennifer Friedlin
To get everyone’s mind off the truly depressing downturn in the capital markets, I set out to write an uplifting column highlighting the fact that most of the companies in the Genome Technology Index have wads of cash to keep going until the market turns up again.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
